News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Oxygen Biotherapeutics, Inc. Cleared to Start Phase II Trials on Oxycyte
August 14, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
bizjournals.com -- Durham drug development company Oxygen Biotherapeutics on Friday announced it has received approval to begin phase II clinical trials in Switzerland for its lead product, a treatment for traumatic brain injury.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Tenax Therapeutics
MORE ON THIS TOPIC
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
·
9 min read
·
Tristan Manalac
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
·
2 min read
·
Tristan Manalac
Women’s Health
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain
July 2, 2025
·
1 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH IQVIA
Understanding the FDA’s AI Guidance in Pharmacovigilance
July 1, 2025
·
1 min read
·
Lori Ellis